Furthermore, treatment of these cell lines with anti-VEGFR1/2 antibodies inhibits proliferation of ESCC cells denotes validity of VEGFRs as the genuine targets in ESCC [60]. This evidence concerns the gene FLT1 and esophageal squamous cell carcinoma.